Our retatrutide mechanism guide explains the receptor science in more detail
Angiology 1995;46(8):705-713
However, with our evolving understanding of the underlying pathophysiology of obesity there are an increasing number of drug targets being identified, and it is anticipated that more medications will be approved by regulatory bodies such as the FDA and EMA to tackle the obesity epidemic
Understanding the established adverse effect profile provides essential context when evaluating less commonly reported symptoms, such as back pain, that patients may experience during treatment
You should consider speaking with a healthcare provider if you experience: Multiple missed periods Severe pelvic pain Extremely heavy bleeding Large blood clots Persistent spotting Severe fatigue or dizziness Sudden dramatic changes in your cycle Concerns about fertility or pregnancy A provider can help determine whether the changes are related to tirzepatide, weight loss, hormone imbalance, PCOS, perimenopause, or another underlying condition
Potential Heart Attack Risk: Although uncommon, reports suggest the need for vigilance in patients with pre-existing heart conditions